The PE Ratio as of November 2024 (TTM) for Akero Therapeutics, Inc. (AKRO) is -8.66

According to Akero Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.66. This represents a change of 30.29% compared to the average of -6.65 of the last 4 quarters.

Akero Therapeutics, Inc. (AKRO) Historical PE Ratio (quarterly & annually)

How has AKRO PE Ratio performed in the past?

The mean historical PE Ratio of Akero Therapeutics, Inc. over the last ten years is -24.61. The current -8.66 PE Ratio has changed 3.42% with respect to the historical average. Over the past ten years (40 quarters), AKRO's PE Ratio was at its highest in in the December 2017 quarter at -1.01. The PE Ratio was at its lowest in in the March 2018 quarter at -230.90.

Akero Therapeutics, Inc. (AKRO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Akero Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Akero Therapeutics, Inc. (AKRO) Average PE Ratio

How has AKRO PE Ratio performed in the past?

The current PE Ratio of Akero Therapeutics, Inc. (AKRO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Akero Therapeutics, Inc. (AKRO) PE Ratio vs. Peers

How is AKRO’s PE Ratio compared to its peers?

Akero Therapeutics, Inc.’s PE Ratio is less than Terns Pharmaceuticals, Inc. (-5.12), greater than Madrigal Pharmaceuticals, Inc. (-14.57), less than Inozyme Pharma, Inc. (-1.84), greater than Viking Therapeutics, Inc. (-58.83), greater than Intercept Pharmaceuticals, Inc. (-91.78), greater than Reata Pharmaceuticals, Inc. (-20.07), greater than Revolution Medicines, Inc. (-16.70), greater than Avidity Biosciences, Inc. (-19.02), less than Protagonist Therapeutics, Inc. (16.80), less than Stoke Therapeutics, Inc. (-6.11), less than TCR2 Therapeutics Inc. (0), less than Black Diamond Therapeutics, Inc. (-0.38), less than Atreca, Inc. (-1.96), less than Passage Bio, Inc. (-0.06), less than null (-0.45),

Build a custom stock screener for Akero Therapeutics, Inc. (AKRO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akero Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Akero Therapeutics, Inc. (AKRO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Akero Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.